ARCHIVES

J&J To Eliminate Its Ortho Biotech Unit As FDA Considers Further Limits On ESAs.

This article is from The Cancer Letter archive.

Vol. 34 No. 17 | May 2, 2008

Download PDF Visit The Full Archive

Related Articles

Protocol Amendments Required For 98 NCI-Sponsored Trials

October 8, 2010

Senate Report Calls For Review Of Progress In Cancer Program Restores Prevention And Control Funding

September 18, 1992

BMI May Be Prognostic Tool For Types Of Breast Cancer

March 28, 2008

Professional Societies: AACR To Establish A Foundation To fund Outreach, Education

April 23, 1999

Communication Is Key To Clinical Trial Enrollment

June 30, 2006

IVAX And It’s Portfolio

December 22, 1994